The EACR & Novosanis research grant for Cancer Biomarker Detection in Urine
Application deadline: 1 September 2021
Research grant of (up to) € 25 000 in support of the most impactful proposal and (up to) 200 Colli-Pee® urine collection devices for use with the project.
Novosanis is offering a research grant exclusive to EACR members to stimulate innovative research in cancer biomarker detection using urine as a sample type. As urine sampling is easy, quick and non-invasive it has the potential to change the way cancer is detected and monitored today. The quality of the urine sample and analytical procedures utilized are critical components to reach this objective.
Urine can not only be used as a liquid biopsy for urogenital tract related cancers such as bladder, prostate, renal, ovarian, endometrial and cervical cancer but also for the detection of thyroid, breast, lung, pancreatic and colorectal cancer. Several biomarker candidates have been identified in urine, in the field of genomics, transcriptomics, proteomics, and metabolomics.
However, collecting a urine sample with a standard urine cup can be awkward, messy and inconvenient for the patient. For this reason, Novosanis developed Colli-Pee®, a device that can be used by both men and women. Colli-Pee® allows for standardized, volumetric collection of the first-void fraction of the urine flow. The device architecture also ensures immediate mixing of urine and preservative for adequate stability, thereby enabling sample storage and transport at room temperature. This allows for home-based collection and large-scale study recruitment.